CL2013002243A1 - Granulado que comprende un nucleo solido en el cual estan dispuestos acido gamma-hidroxibutirico o una sal del mismo, compuestos que pueden generar evolucion de gas, diluyentes, un aglutinante y una membrana de recubrimiento; composicion farmaceutica; y uso para tratar la narcolepsia y abstinencia alcoholica. - Google Patents
Granulado que comprende un nucleo solido en el cual estan dispuestos acido gamma-hidroxibutirico o una sal del mismo, compuestos que pueden generar evolucion de gas, diluyentes, un aglutinante y una membrana de recubrimiento; composicion farmaceutica; y uso para tratar la narcolepsia y abstinencia alcoholica.Info
- Publication number
- CL2013002243A1 CL2013002243A1 CL2013002243A CL2013002243A CL2013002243A1 CL 2013002243 A1 CL2013002243 A1 CL 2013002243A1 CL 2013002243 A CL2013002243 A CL 2013002243A CL 2013002243 A CL2013002243 A CL 2013002243A CL 2013002243 A1 CL2013002243 A1 CL 2013002243A1
- Authority
- CL
- Chile
- Prior art keywords
- binder
- compounds
- gamma
- pharmaceutical composition
- solid core
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000011230 binding agent Substances 0.000 title abstract 3
- 239000003085 diluting agent Substances 0.000 title abstract 3
- 239000012528 membrane Substances 0.000 title abstract 3
- 239000011248 coating agent Substances 0.000 title abstract 2
- 238000000576 coating method Methods 0.000 title abstract 2
- 239000008187 granular material Substances 0.000 title abstract 2
- 201000003631 narcolepsy Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 title 1
- 208000029650 alcohol withdrawal Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 3
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical class [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 239000011575 calcium Chemical class 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229920002678 cellulose Chemical class 0.000 abstract 1
- 239000001913 cellulose Chemical class 0.000 abstract 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 150000003109 potassium Chemical class 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
UN GRÁNULO QUE COMPRENDE UN NÚCLEO SÓLIDO SOBRE EL QUE SE APOYA UN INGREDIENTE ACTIVO, EN DONDE DICHO INGREDIENTE ACTIVO SE SELECCIONA DE ÁCIDO GAMMA-HIDROXIBUTÍRICO O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, EL GRÁNULO CARACTERIZADO PORQUE COMPRENDE ADEMÁS, APOYADOS SOBRE DICHO NÚCLEO SÓLIDO, LOS SIGUIENTES COMPUESTOS: • UNO O VARIOS COMPUESTOS QUE PUEDEN GENERAR EVOLUCIÓN DE GAS, • UNO O VARIOS DILUYENTES, • UN AGLUTINANTE, • UNA MEMBRANA DE RECUBRIMIENTO, DONDE DICHO GRÁNULO SE CARACTERIZA PORQUE CONSISTE DE: • 15-25% DE NÚCLEO SÓLIDO SELECCIONADO DEL GRUPO QUE CONSISTE EN POLIOLES, GOMAS, DERIVADOS DE SÍLICE, DERIVADOS DE CALCIO O POTASIO, COMPUESTOS MINERALES, SACAROSA, DERIVADOS DE CELULOSA, ALMIDÓN Y MEZCLAS DE LOS MISMOS, • 50 A 60% DE INGREDIENTE ACTIVO, • 5 A 15% DE BICARBONATO DE SODIO, COMO GENERADOR DE GAS, • 2 A 18% DE ALUMINOMETASILICATO DE MAGNESIO, COMO DILUYENTE, • 3-10% DE GOMA LACA, COMO AGLUTINANTE, • 2-5% DE MEMBRANA DE RECUBRIMIENTO EXTERIOR, EN PESO RESPECTO AL PESO TOTAL DEL GRÁNULO. ADEMAS DE UNA COMPOSICIÓN FARMACÉUTICAQUE ES ÚTIL EN NARCOLEPSIA Y PRIVACIÓN DEL ALCOHOLISMO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1100433A FR2971422B1 (fr) | 2011-02-11 | 2011-02-11 | Granules d'acide gamma-hydroxybutyrique |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013002243A1 true CL2013002243A1 (es) | 2014-01-31 |
Family
ID=45819229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013002243A CL2013002243A1 (es) | 2011-02-11 | 2013-08-06 | Granulado que comprende un nucleo solido en el cual estan dispuestos acido gamma-hidroxibutirico o una sal del mismo, compuestos que pueden generar evolucion de gas, diluyentes, un aglutinante y una membrana de recubrimiento; composicion farmaceutica; y uso para tratar la narcolepsia y abstinencia alcoholica. |
Country Status (30)
Country | Link |
---|---|
US (2) | US9943488B2 (es) |
EP (1) | EP2672961B1 (es) |
JP (1) | JP5869004B2 (es) |
KR (1) | KR101799620B1 (es) |
CN (1) | CN103347503B (es) |
AR (1) | AR085360A1 (es) |
AU (1) | AU2012215252C1 (es) |
BR (1) | BR112013020412B1 (es) |
CA (1) | CA2825053C (es) |
CL (1) | CL2013002243A1 (es) |
CY (1) | CY1120655T1 (es) |
DK (1) | DK2672961T3 (es) |
EA (1) | EA026403B1 (es) |
ES (1) | ES2680638T3 (es) |
FR (1) | FR2971422B1 (es) |
HK (1) | HK1185007A1 (es) |
HR (1) | HRP20181338T1 (es) |
HU (1) | HUE039484T2 (es) |
IL (1) | IL227631A (es) |
LT (1) | LT2672961T (es) |
MA (1) | MA34886B1 (es) |
MX (1) | MX362613B (es) |
PL (1) | PL2672961T3 (es) |
PT (1) | PT2672961T (es) |
RS (1) | RS57615B1 (es) |
SI (1) | SI2672961T1 (es) |
TR (1) | TR201811120T4 (es) |
TW (1) | TWI533865B (es) |
UA (1) | UA113506C2 (es) |
WO (1) | WO2012107652A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011232408B2 (en) | 2010-03-24 | 2015-07-30 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
FR3049463B1 (fr) | 2016-04-01 | 2019-07-05 | Debregeas Et Associes Pharma | Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) * | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
RU2663466C1 (ru) * | 2017-03-20 | 2018-08-06 | Общество с ограниченной ответственностью "МБА-групп" | Композиция для профилактики и/или лечения вич-инфекции |
EA202091127A1 (ru) * | 2017-11-02 | 2020-09-22 | Замбон С.П.А. | Фармацевтические композиции, включающие сафинамид |
US11337920B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release |
WO2019126218A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
IL275312B1 (en) | 2017-12-18 | 2024-05-01 | Tris Pharma Inc | GHB pharmacy preparations containing a system that creates a floating integrated penetrating polymer network |
WO2019123269A1 (en) * | 2017-12-20 | 2019-06-27 | Flamel Ireland Limited | Packaged modified release gamma-hydroxybutyrate formulations having improved stability |
CA3115122A1 (en) | 2018-11-19 | 2020-05-28 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物 |
CA3183185A1 (en) | 2020-06-18 | 2021-12-23 | Jia-Ning Xiang | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
CN116261451A (zh) | 2020-07-24 | 2023-06-13 | 凯瑞康宁生物工程有限公司 | γ-羟基丁酸衍生物的药物组合物和药物动力学 |
CA3194665A1 (en) | 2020-10-05 | 2022-04-14 | Jia-Ning Xiang | Modified release compositions of a gamma-hydroxybutyric acid derivative |
CN117098533A (zh) | 2021-03-19 | 2023-11-21 | 凯瑞康宁公司 | γ-羟基丁酸衍生物的组合释放型制剂的药物动力学 |
WO2022218364A1 (en) * | 2021-04-16 | 2022-10-20 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | Coated beta hydroxybutyric acid crystal and methods for producing the same |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1266565B1 (it) | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
ITMI20011446A1 (it) * | 2001-07-06 | 2003-01-06 | Altergon Sa | Composizioni farmaceutiche di principi attivi suscettibili di somministrazione illecita |
US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
FR2938431B1 (fr) * | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
FR2938432B1 (fr) * | 2008-11-14 | 2011-05-20 | Debregeas Et Associes Pharma | Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus |
FR2949062B1 (fr) * | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
-
2011
- 2011-02-11 FR FR1100433A patent/FR2971422B1/fr active Active
-
2012
- 2012-02-03 ES ES12708564.5T patent/ES2680638T3/es active Active
- 2012-02-03 BR BR112013020412-5A patent/BR112013020412B1/pt active IP Right Grant
- 2012-02-03 TR TR2018/11120T patent/TR201811120T4/tr unknown
- 2012-02-03 LT LTEP12708564.5T patent/LT2672961T/lt unknown
- 2012-02-03 DK DK12708564.5T patent/DK2672961T3/en active
- 2012-02-03 PL PL12708564T patent/PL2672961T3/pl unknown
- 2012-02-03 CA CA2825053A patent/CA2825053C/fr active Active
- 2012-02-03 PT PT12708564T patent/PT2672961T/pt unknown
- 2012-02-03 HU HUE12708564A patent/HUE039484T2/hu unknown
- 2012-02-03 WO PCT/FR2012/000046 patent/WO2012107652A1/fr active Application Filing
- 2012-02-03 RS RS20180977A patent/RS57615B1/sr unknown
- 2012-02-03 EA EA201300902A patent/EA026403B1/ru not_active IP Right Cessation
- 2012-02-03 US US13/984,922 patent/US9943488B2/en active Active
- 2012-02-03 AU AU2012215252A patent/AU2012215252C1/en active Active
- 2012-02-03 KR KR1020137020804A patent/KR101799620B1/ko active IP Right Grant
- 2012-02-03 MX MX2013008299A patent/MX362613B/es active IP Right Grant
- 2012-02-03 SI SI201231360T patent/SI2672961T1/sl unknown
- 2012-02-03 MA MA36151A patent/MA34886B1/fr unknown
- 2012-02-03 EP EP12708564.5A patent/EP2672961B1/fr active Active
- 2012-02-03 CN CN201280008043.3A patent/CN103347503B/zh active Active
- 2012-02-03 JP JP2013552999A patent/JP5869004B2/ja active Active
- 2012-02-09 TW TW101104142A patent/TWI533865B/zh active
- 2012-02-10 AR ARP120100442A patent/AR085360A1/es unknown
- 2012-03-02 UA UAA201310282A patent/UA113506C2/uk unknown
-
2013
- 2013-07-24 IL IL227631A patent/IL227631A/en active IP Right Grant
- 2013-08-06 CL CL2013002243A patent/CL2013002243A1/es unknown
- 2013-11-05 HK HK13112413.9A patent/HK1185007A1/zh unknown
-
2018
- 2018-03-06 US US15/912,640 patent/US20180193277A1/en not_active Abandoned
- 2018-08-22 HR HRP20181338TT patent/HRP20181338T1/hr unknown
- 2018-09-04 CY CY181100921T patent/CY1120655T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013002243A1 (es) | Granulado que comprende un nucleo solido en el cual estan dispuestos acido gamma-hidroxibutirico o una sal del mismo, compuestos que pueden generar evolucion de gas, diluyentes, un aglutinante y una membrana de recubrimiento; composicion farmaceutica; y uso para tratar la narcolepsia y abstinencia alcoholica. | |
AR116907A2 (es) | Derivado de diazabiciclooctano ópticamente activo y proceso para su preparación | |
ES2563323T3 (es) | Procedimiento para la preparación de un sólido cristalino a partir de derivados de ácido glicin-N,N-diacético | |
PE20141358A1 (es) | Polimorfos de inhibidores de cinasas | |
CY1118093T1 (el) | Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt | |
PE20190734A1 (es) | Composiciones de colector y metodos de uso de las mismas | |
EA201270216A1 (ru) | Фармацевтический состав | |
CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
CL2011003072A1 (es) | Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras. | |
UY32490A (es) | Inhibidores de beta-secretasa | |
BR112013016595A2 (pt) | inibidores de neprilisina | |
UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
CR20140195A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas | |
HN2010002121A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak | |
CR20150663A (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
CY1112865T1 (el) | Συν-κρυσταλλοι και φαρμακευτικες συνθεσεις που τους περιεχουν | |
MA35749B1 (fr) | Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc | |
AR088564A1 (es) | PROCESO PARA LA PREPARACION DE AGONISTAS Y COMPUESTOS INTERMEDIOS DE b3 | |
BR112014029551A2 (pt) | compostos de ácido dimetil-benzoico | |
BR112013011593A2 (pt) | cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo | |
CR20140218A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii | |
CR20140217A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii | |
ES2532451T3 (es) | Composición herbicida | |
AR091687A1 (es) | Formas solidas de inhibidores de fosfodiesterasa tipo 5 | |
EA201391371A1 (ru) | Фармацевтическая композиция ситаглиптина |